Novel Transdermal Delivery Technology

Dyve’s technology fluidizes the stratum corneum lipid matrix and modulates cellular junctions to transiently create a paracellular drug delivery pathway that leverages the body’s largest organ – the skin – as a delivery portal.

Broad applicability

Data set in pre-clinical and human testing across a range of molecules demonstrates ability to overcome historically challenging chemical characteristics (size, solubility, lipophilicity, etc.).

PK + efficacy validation

In a pay-load and platform specific way, we’ve shown robust pharmacokinetic and efficacy benefits versus existing routes of delivery – fast, efficient, and convenient dosing that non-invasively bypasses GI challenges for local or systemic delivery.